UK MHRA Approves CAMP4 ASCEND + USA Today + Rare-X/Citizen Health + 6 Things #S10E219

Friday, September 11, 2026 — Week 37

CAMP4 — ASCEND EXPANDS TO THE UK

UK MHRA authorizes UK sites in CAMP4's Phase 1/2 CMP-002 trial.

UK joins Australia + Argentina. EU filing remains under review.

First-in-human trial still targeted to begin Q4 2026.

Another major step toward our first disease-modifying clinical trial.https://investors.camp4tx.com/news-releases/news-release-details/camp4-therapeutics-receives-authorization-united-kingdom-phase

CAMP4 ANALYST DAY — SEPT. 28

12–1:30 PM ET. Trial design + unmet need + early pipeline.

CURE SYNGAP1 participating https://investors.camp4tx.com/news-events/events

We will have a day after, webinar, stay tuned for details.

USA TODAY — SYNGAP1 IN PRINT

SYNGAP1 family story appeared in USA TODAY's national print edition this week.